Protein Profiling of B-Cell Lymphomas Using Tissue Biopsies: A Potential Tool for Small Samples in Pathology

Autor: Corine Jansen, Konnie M. Hebeda, Marianne Linkels, Johanna M. M. Grefte, John M. M. Raemaekers, Johan H. J. M. van Krieken, Patricia J. T. A. Groenen

Publikováno v: Cellular Oncology, Vol 30, Iss 1, Pp 27-38 (2008)

Non-Hodgkin’s lymphoma comprises many related but distinct diseases and diagnosis and classification is complex. Protein profiling of lymphoma biopsies may be of potential value for use in this lymphoma classification and the discovery of novel mar

Externí odkaz: https://doaj.org/article/391259bbe3714356b2dc0b2de334659f

Application of microfluidic technology to the BIOMED-2 protocol for detection of B-cell clonality

Autor: Marco Chilosi, Francesca Mancini, Annemiek W.M. van Raaij, Alberto Zamò, Marina Montresor, Anna Bertolaso, Aldo Scarpa, Maria Scardoni, Johan H. J. M. van Krieken, Fabio Menestrina, Patricia J. T. A. Groenen

Publikováno v: Journal of Molecular Diagnostics, 14, 30-7
Journal of Molecular Diagnostics, 14, 1, pp. 30-7

Contains fulltext : 109691.pdf (Publisher’s version ) (Closed access) The BIOMED-2 protocol is widely used for detecting clonality in lymphoproliferative disorders. The protocol requires multiple PCR reactions, which are analyzed by either capillar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b1d064559dcea05dd20759962ba76ab
https://doi.org/10.1016/j.jmoldx.2011.07.007

Mutation analysis of KRAS prior to targeted therapy in colorectal cancer: development and evaluation of quality by a European external quality assessment scheme

Autor: Sara Vander Borght, Marjolijn J L Ligtenberg, Johan H. J. M. van Krieken, Elisabeth Dequeker

Publikováno v: Virchows Archiv, 459, 155-60
Virchows Archiv, 459, 2, pp. 155-60

Contains fulltext : 96128.pdf (Publisher’s version ) (Closed access) In Europe, the use of anti-EGFR monoclonal antibodies is restricted to Kirsten RAS (KRAS) wild-type colorectal tumors. Information on the KRAS status of the patients tumor is thus

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95bc89e467ce2fa9ea2efe64fcd3c816
https://doi.org/10.1007/s00428-011-1094-x

Lymph Node Retrieval in Rectal Cancer is Dependent on Many Factors—the Role of the Tumor, the Patient, the Surgeon, the Radiotherapist, and the Pathologist

Autor: Iris D. Nagtegaal, Corrie A.M. Marijnen, Leonie J. M. Mekenkamp, Johan H. J. M. van Krieken, Cornelis J.H. van de Velde

Publikováno v: American Journal of Surgical Pathology. 33:1547-1553

Lymph node status is the strongest prognostic factor for survival in colorectal cancer. There are several guidelines concerning the minimum numbers of lymph nodes that need to be examined to make reliable staging possible, but there is no consensus i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cc49422a62659aeec262edba27fadc6
https://doi.org/10.1097/pas.0b013e3181b2e01f

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

Autor: Miriam Koopman, Cees J van Groeningen, Ninja Antonini, Jeroen R. Dijkstra, Marianne E. Vink-Börger, Otilia Dalesio, Dirk J. Richel, A. Vos, C.J. Rodenburg, Annemieke Cats, Harm Sinnige, Geert Jan Creemers, Cornelis J. A. Punt, Jolien Tol, Emile E. Voest, Frans L. G. Erdkamp, Linda Mol, Jolanda G Schrama, Johan H. J. M. van Krieken

Publikováno v: New England journal of medicine, 360(6), 563-572. Massachussetts Medical Society
The New England Journal of Medicine, 360, 563-72
de Nooy-van Tol, J, Koopman, M, Cats, A, Rodenburg, C J, Creemers, G J M, Schrama, J G, Erdkamp, F L G, Vos, A H, van Groeningen, C J, Sinnige, H A M, Richel, D J, Voest, E E, Dijkstra, J R, Vink-Borger, M E, Antonini, N F, Mol, L, van Krieken, J H J M, Dalesio, O & Punt, C J A 2009, ' Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer ', New England Journal of Medicine, vol. 360, no. 6, pp. 563-572 . https://doi.org/10.1056/NEJMoa0808268
The New England Journal of Medicine, 360, 6, pp. 563-72
New England Journal of Medicine, 360(6), 563-572. Massachussetts Medical Society
The New England journal of medicine, 360(6), 563-572. Massachussetts Medical Society

Contains fulltext : 79995.pdf (Publisher’s version ) (Open Access) BACKGROUND: Fluoropyrimidine-based chemotherapy plus the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab is standard first-line treatment for metastatic colorect

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91d4f0da267a28af2516fc8e5e361490
https://doi.org/10.1056/NEJMoa0808268